Vysov D (Vildagliptin/Dapagliflozin)

Product Overview

Vysov D is a prescription oral antidiabetic medication formulated by Cipla Limited for the management of type 2 diabetes mellitus. Each tablet delivers a fixed‑dose combination of 100 mg vildagliptin and 5 mg dapagliflozin, two pharmacologically distinct agents that act through complementary mechanisms to improve glycaemic control. The product is supplied in strips containing 10 tablets, with pack sizes of 60, 120, or 240 tablets to accommodate individualized therapy regimens. Vysov D is indicated for patients who require dual‑action glucose‑lowering therapy and is intended to be used alongside diet and exercise. For more detailed prescribing information, refer to the official Cipla product monograph or consult a healthcare professional.

What is Vysov D?

Vysov D (Vildagliptin/Dapagliflozin) belongs to a class of medicines known as dipeptidyl peptidase‑4 (DPP‑4) inhibitors combined with sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors. Vildagliptin enhances incretin hormone activity, thereby stimulating insulin secretion and suppressing glucagon release in a glucose‑dependent manner. Dapagliflozin, on the other hand, promotes renal glucose excretion by inhibiting SGLT‑2 in the proximal tubule. The synergistic effect of these two agents provides robust HbA1c reduction while offering cardiovascular and renal benefits that are particularly relevant for patients with type 2 diabetes who have additional risk factors such as hypertension or dyslipidaemia. Clinical studies have demonstrated that the fixed‑dose combination can achieve target glucose levels more efficiently than either component used alone.

Uses and Benefits

The primary use of Vysov D is to improve glycaemic control in adults with type 2 diabetes mellitus who have not achieved adequate glucose regulation with monotherapy. In addition to lowering blood glucose, the medication has been shown to reduce the risk of major cardiovascular events, including myocardial infarction and stroke, especially in patients with established cardiovascular disease. The SGLT‑2 component also confers modest weight loss and lowers blood pressure, contributing to an overall favourable metabolic profile. For patients with early‑stage chronic kidney disease, the dapagliflozin portion may slow progression of renal impairment. These cardiovascular and renal advantages make Vysov D an attractive option for comprehensive diabetes management, aligning with guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

How It Works

Vildagliptin functions by binding to the DPP‑4 enzyme, preventing the degradation of incretin hormones such as GLP‑1 and GIP. This leads to enhanced glucose‑dependent insulin secretion and reduced glucagon release, resulting in lower post‑prandial glucose excursions without causing hypoglycaemia when used as monotherapy. Dapagliflozin acts upstream in the kidney, inhibiting the SGLT‑2 protein that reabsorbs glucose from the filtrate. By blocking this transporter, dapagliflozin forces excess glucose to be excreted in the urine, thereby reducing plasma glucose concentrations independent of insulin pathways. The combined pharmacodynamics of these two agents provide a dual‑targeted approach that addresses both insulin secretory defects and renal glucose handling. For an in‑depth scientific review, see the PubMed database or the National Institutes of Health (NIH) resource on diabetes therapeutics.

Dosage Guidelines

The recommended starting dose of Vysov D is one tablet taken orally once daily, preferably with or without food, at the same time each day. The fixed‑dose strength is 100 mg vildagliptin and 5 mg dapagliflozin per tablet. Patients should be instructed to swallow the tablet whole with a sufficient amount of water. If renal function declines, dosage adjustment may be necessary; therefore, periodic assessment of estimated glomerular filtration rate (eGFR) is advised. In patients with moderate renal impairment (eGFR 45–59 mL/min/1.73 m²), the dose should be reduced to half a tablet daily, while those with severe renal impairment (eGFR <45 mL/min/1.73 m²) should avoid use. Hepatic impairment does not require dose modification, but caution is warranted in patients with concomitant medications that affect the CYP450 enzyme system. Always follow the prescribing information provided by Cipla Limited or your healthcare provider.

Side Effects

Like all pharmaceutical products, Vysov D may be associated with adverse effects. The most commonly reported side effects include urinary tract infections, genital mycotic infections, increased urinary frequency, and mild hypoglycaemia when combined with insulin or sulfonylureas. Less frequent but clinically important adverse events comprise ketoacidosis, pancreatitis, and hepatic enzyme elevations. Patients should be advised to monitor for signs of dehydration, such as dizziness or reduced urine output, and to seek medical attention if they experience persistent nausea, vomiting, or abdominal pain. Rarely, hypersensitivity reactions such as rash or angioedema may occur. For a comprehensive list of side effects, consult the FDA prescribing information or the Drugs.com database.

Warnings and Precautions

Vysov D is contraindicated in patients with a history of hypersensitivity to vildagliptin, dapagliflozin, or any component of the formulation. The medication should not be used in individuals with type 1 diabetes or diabetic ketoacidosis. Caution is recommended in patients with a history of renal disease, cardiovascular disease, or those undergoing surgery or procedures that may affect renal perfusion. Concomitant use with insulin or strong insulin secretagogues may increase the risk of hypoglycaemia; dose adjustments of the accompanying therapy may be necessary. Patients should avoid excessive alcohol consumption and maintain adequate hydration to reduce the risk of volume depletion. Pregnant or breastfeeding women should not use Vysov D, as safety data are lacking. For official regulatory guidance, refer to the U.S. Food and Drug Administration (FDA) labeling.

Frequently Asked Questions

1. Can Vysov D be taken with other diabetes medications? Yes, Vysov D can be used in combination with metformin, but dose adjustments may be required for insulin or sulfonylureas to prevent hypoglycaemia. Always consult your physician before adding or removing any medication.
2. How long does it take to see improvements in blood glucose levels? Clinical studies indicate that a measurable reduction in HbA1c can be observed within 12 weeks of consistent daily use, although individual response may vary based on baseline glucose control and adherence.
3. Is the medication safe for patients with kidney problems? Vysov D should be used with caution in patients with moderate renal impairment; a reduced dose of half a tablet daily is recommended. It is not recommended for patients with severe renal impairment (eGFR <45 mL/min/1.73 m²).
4. What should I do if I miss a dose? If you remember a missed dose within 12 hours, take it as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.
5. Where can I find more detailed prescribing information? Detailed prescribing information is available on the Cipla Limited official website, as well as on reputable medical resources such as the MedlinePlus page for antidiabetic agents or the Wikipedia entry on type 2 diabetes.

For additional support, patients can contact Cipla Limited’s customer service or their healthcare provider to discuss any questions regarding treatment. Proper storage at room temperature, away from moisture and heat, will maintain the integrity of the tablets throughout the pack’s shelf life.